anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acid sphingomyelinase deficiency is a neurodegenerative lysosomal storage disorder caused by mutations in the sphingomyelin-degrading enzyme acid sphingomyelinase (ASM) gene. Upregulated neuroinflammation has been well-characterized in an ASM knockout mouse model of acid sphingomyelinase deficiency disease, but lipid mediator pathways involved in 'mediating' inflammation and inflammation-resolution have yet to be characterized. In this study, we 1) measured free (bioactive) and esterified (inactive) lipid mediators involved in inflammation and inflammation resolution in cerebellum and neuronal cultures of ASM knockout (ASMko) mice and wildtype (WT) controls, and 2) quantified the esterification of labeled pro-resolving free d11-14(15)-epoxyeicosatrienoic acid in cultured neurons from ASMko and WT mice. We found elevated concentrations of esterified pro-resolving lipid mediators and hydroxyeicosatrienoic acids typically destined for pro-resolving lipid mediator synthesis (e.g. lipoxins) in the cerebellum and neurons of ASMko mice compared to controls. Free d11-14(15)-epoxyeicosatrienoic acid esterification within neurons of ASMko mice was significantly elevated compared to WT. Our findings show evidence of increased inactivation of free pro-resolving lipid mediators through esterification in ASMko mice, suggesting impaired resolution as a new pathway underlying ASM deficiency pathogenesis.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of stably keeping prostaglandin E1 even in long-term storage and useful for treatment of male sexual function disorder such as impotentia erigendi by dissolving prostaglandin E1 in sodium citrate/citric acid buffer solution and subjecting the solution to germ-free filtration and freeze-drying. SOLUTION: This injection composition is obtained by dissolving (A) prostaglandin E1 in (B) sodium citrate/citric acid buffer solution, preferably in a ratio of 160,000-180,000 pts.vol. component B to 1 pt.vol. component A and subjecting the solution to aseptic filtration and freeze-drying. The component A is preferably included by a cyclodextrin (preferably α-cyclodextrin), preferably in an amount of 30-35 pts.wt. based on 1 pt.wt. component A.
OBJECTIVES: Cervical cancer accounts for 10 percent of cancer deaths among women in India. The human papillomavirus (HPV) vaccine can protect against infection but it is not included in India's universal immunisation programme. This study aimed to assess the demand and willingness to pay for the HPV vaccine among mothers of adolescent daughters.
METHODS: We conducted a contingent valuation exercise involving a hospital-based cross-sectional study to assess the demand for an HPV vaccine among mothers of adolescent daughters, their willingness to pay and its determinants. Participants were recruited at a tertiary care civil hospital in the city of Gurgaon in North India, and data was collected from December 2018 to February 2019. A questionnaire was administered to obtain demographic and awareness indicators. Payment cards were used to elicit the willingness to pay amount.
RESULTS: Out of 319 respondents, 79% were willing to pay for the vaccine. The mean maximum willingness to pay was INR 629 (USD 35), which was less than the vaccine market price of INR 2000-3000 (USD 117-175) per dose. Participant age and number of children significantly influenced demand, while family income and awareness of cervical cancer influenced willingness to pay for the HPV vaccine. Participants were willing to spend between 3% and 34% of their monthly income on the vaccine.
CONCLUSIONS: High demand and low willingness to pay for the HPV vaccine indicate low value perception of the health outcome among mothers of adolescent children in India. A strategy aimed at a price reduction of the vaccine and increasing its demand through improved awareness is important. At the same time, subsidising the vaccine in the short run is needed.
Participants received Androderm® 4 mg, transdermal dose, once daily (QD) for up to 16 weeks. At Day 14, if serum concentration was less than 400 nanograms per deciliter (ng/dL), the dose was increased to 6 mg, transdermal dose, QD for up to 16 weeks and if the serum concentration was more than 930 ng/dL, the dose was decreased to 2 mg, transdermal dose, QD for up to 16 weeks. The dose was not adjusted if serum concentrations were within the normal range.
The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2\* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
PURPOSE: To obtain a cell adhesion inhibitor containing a hydroxylbenzoic acid derivative as an active ingredient, useful for immune suppression and preventing and treating an inflammations, allergies and cancer metastases. CONSTITUTION: This cell adhesion inhibitor contains 0.01-50wt.% of a compound of the formula (X is O or NH; R<1> is OH or a 4-25C hydrocarbon which may contain a hetero atom; R<2> is H, OH or a 1-3C alkoxyl; Y is OR3 , etc.; R3 is H, an alkyl, etc.) or its salt as an active ingredient. The compound of the formula has low cytotoxicity, excellent inhibitory action on cell adhesion and is useful as an antiinflammatory agent, an antiallergic agent, a cancer metastasis inhibitor and an immunosuppressive agent. The cell adhesion inhibitor is widely effective for preventing and treating bronchitis, asthma, allergic rhinitis, gout, arthritis, nephritis, hepatitis, rheumatism, pollinosis, urticaria, ischemic reperfusion interceptive acute breath stress syndrome, acute alveolopathy, autoimmune disease, psoriasis, contact dermatitis, atopic dermatitis, UV inflammation, etc.  The cell adhesion inhibitor is administered orally or enterally as an external preparation. A daily dose is 1-100mg/kg.
An orally ingestible solid penicillin composition in dosage unit form and of specified potency comprises penicillin, a solid pharmaceutical vehicle and a chelating agent, said chelating agent being a salt of ethylenediamine tetraacetic acid, the actual content of penicillin in said composition being not substantially in excess of that theoretically required to impart said specified potency to the composition and the potency of said composition as determined by assay being substantially identical with said specified potency within the limits of experimental accuracy.  The penicillin may be any penicillin, e.g. penicillin 9 or penicillin V, or any therapeutic form thereof, e.g. potassium salt.  The preferred chelating agent is the disodium salt of ethylenediamine tetra-acetic acid.  The preparations preferably contain calcium carbonate.
Acute bacterial orchitis (AO) is a prevalent cause of intrascrotal inflammation, often resulting in sub- or infertility. A frequent cause eliciting AO is uropathogenic Escherichia coli (UPEC), a gram negative pathovar, characterized by the expression of various iron acquisition systems to survive in a low-iron environment. On the host side, iron is tightly regulated by iron regulatory proteins 1 and 2 (IRP1 and -2) and these factors are reported to play a role in testicular and immune cell function; however, their precise role remains unclear. Here, we showed in a mouse model of UPEC-induced orchitis that the absence of IRP1 results in less testicular damage and a reduced immune response. Compared with infected wild-type (WT) mice, testes of UPEC-infected Irp1-/- mice showed impaired ERK signaling. Conversely, IRP2 deletion led to a stronger inflammatory response. Notably, differences in immune cell infiltrations were observed among the different genotypes. In contrast with WT and Irp2-/- mice, no increase in monocytes and neutrophils was detected in testes of Irp1-/- mice upon UPEC infection. Interestingly, in Irp1-/- UPEC-infected testes, we observed an increase in a subpopulation of macrophages (F4/80+CD206+) associated with antiinflammatory and wound-healing activities compared with WT. These findings suggest that IRP1 deletion may protect against UPEC-induced inflammation by modulating ERK signaling and dampening the immune response.
INTRODUCTION: Pediatric prucalopride studies for treatment of gastrointestinal (GI) disorders have reported mixed results. We aimed to assess the safety and effectiveness of prucalopride in functional constipation (FC) with and without upper GI symptoms.
METHODS: Retrospective data on patients with FC receiving combined prucalopride and conventional therapy was compared with those receiving conventional therapy alone within 12 months. Thirty patients on combined therapy and those on conventional therapy were each matched on the basis of age, gender, race, and presence of fecal soiling. Response (complete, partial, or no resolution) was compared. Similarly, response to concurrent functional upper GI symptoms (postprandial pain, bloating, weight loss, vomiting, early satiety, or nausea) and dysphagia, as well as adverse effects, were evaluated in the combined group.
RESULTS: Mean age of 57 cases was 14.7 ± 4.9 years and 68% were female. Comorbidities included functional upper GI (UGI) symptoms (84%), dysphagia (12%), mood disorders (49%), and hypermobility spectrum disorder (37%). Unmatched cases reported 63% improvement to FC; response did not differ between the matched cohorts (70% versus 76.6%, p = 0.84). Cases showed a 56% improvement in functional UGI symptoms and 100% in dysphagia. Adverse effects were reported in 30%, abdominal cramps being most common. Four (7%) patients with a known mood disorder reported worsened mood, of which two endorsed suicidal ideation.
CONCLUSION: Prucalopride efficaciously treated concurrent UGI symptoms and dysphagia in constipated pediatric patients and was overall well tolerated. Preexisting mood disorders seemed to worsen in a small subset of cases.
Epidermolysis bullosa (EB) is an umbrella term for a group of rare inherited skin disorders characterised by mucocutaneous fragility. Patients suffer from blisters and chronic wounds that arise spontaneously or following minor mechanical trauma, often resulting in inflammation, scarring and fibrosis due to poor healing. The recessive form of dystrophic EB (RDEB) has a particularly severe phenotype and is caused by mutations in the COL7A1 gene, encoding the collagen VII protein, which is responsible for adhering the epidermis and dermis together. One of the most feared and devastating complications of RDEB is the development of an aggressive form of cutaneous squamous cell carcinoma (cSCC), which is the main cause of mortality in this patient group. However, pathological drivers behind the development and progression of RDEB-associated cSCC (RDEB-cSCC) remain somewhat of an enigma, and the evidence to date points towards a complex process. Currently, there is no cure for RDEB-cSCC, and treatments primarily focus on prevention, symptom management and support. Therefore, there is an urgent need for a comprehensive understanding of this cancer's pathogenesis, with the aim of facilitating the discovery of drug targets. This review explores the current knowledge of RDEB-cSCC, emphasising the important role of the immune system, genetics, fibrosis, and the tumour-promoting microenvironment, all ultimately intricately interconnected.
PURPOSE:To obtain the titled drug preparation having remarkably improved absorptivity of an active substance through nasal mucosa into blood, exhibiting low local toxicity and stimulation and resistant to decomposition of the active component, by suppressing the osmotic pressure ratio of the aqueous solution of the active substance below a specific level. CONSTITUTION:The titled drug preparation having improved absorptivity of an active substance through the nasal mucosa into blood, exhibiting effective activity to release growth hormone at a low rate of administration without accompanying harmful reaction and able to be easily administered can be produced by suppressing the osmotic pressure ratio of an aqueous solution of the active substance to <=1 (preferably 0.3-0.1). The osmotic pressure ratio is a relative ratio to physiological osmotic pressure and the content of the active substance in the drug preparation is preferably 0.01-10W/V% in aqueous solution. The above drug preparation can be prepared by mixing and dissolving necessary components in distilled water and adjusting to a prescribed osmotic pressure ratio. It can be converted to a powdery preparation to be dissolved before using e.g. by freeze-drying.
Disturbed sleep is stressful to persons living with dementia (PLwD) and their caregivers. It contributes to the earlier placement of the PLwD in nursing homes and increases the risk for many psychological and cognitive health issues and poor quality of life for both the PLwD and the caregivers. Given the potential harmful side effects of medications, non-medication alternatives, such as Cognitive Behavioral Therapy for Insomnia (CBTi), may be safer to improve disturbed sleep in this population. CBTi which includes stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring, is effective and has durable and sustained effects on sleep outcomes over the long term. CBTi has improved sleep disturbances in PLwD and their caregivers, separately. Since disturbed sleep in the PLwD-caregiver dyad is bidirectional and interdependent, targeting the pair as a unit for intervention has the potential to lead to improved sleep and health outcomes for both persons.

There is no current published research on CBTi when the PLwD and their caregivers receive the intervention at the same time; as a result, the research team aims to examine the 1) feasibility and 2) preliminary efficacy of 6-week CBTi intervention for community-dwelling PLwD and their caregivers who are both experiencing sleep disturbances. PLwD-caregiver dyads will participate in videoconferencing sessions. In addition, semi-structured interviews will take place to examine the acceptability and satisfaction with the intervention.
The pharmacokinetics of etodolac following administration of etodolac extended-release tablets have not been investigated in subjects with renal insufficiency. Etodolac renal clearance following administration of etodolac tablets was unchanged in the presence of mild-to-moderate renal failure (creatinine clearance, 37 to 88 mL/min). Although renal elimination is a significant pathway of excretion for etodolac metabolites, no dosing adjustment in patients with mild to moderate renal dysfunction is generally necessary. Etodolac plasma protein binding decreases in patients with severe renal deficiency. Etodolac should be used with caution in such patients because, as with other NSAIDs, it may further decrease renal function in some patients. Etodolac is not significantly removed from the blood in patients undergoing hemodialysis.
AIMS: Gene therapies to induce cardiomyocyte (CM) cell cycle re-entry have shown a potential to treat subacute ischaemic heart failure (IHF) but have not been tested in the more relevant setting of chronic IHF. Our group recently showed that polycistronic non-integrating lentivirus encoding Cdk1/CyclinB1 and Cdk4/CyclinD1 (TNNT2-4Fpolycistronic-NIL) is effective in inducing CM cell cycle re-entry and ameliorating subacute IHF models and preventing the subsequent IHF-induced congestions in the liver, kidneys, and lungs in rats and pigs. Here, we aim to test the long-term efficacy of TNNT2-4Fpolycistronic-NIL in a rat model of chronic IHF, a setting that differs pathophysiologically from subacute IHF and has greater clinical relevance.
METHODS AND RESULTS: Rats were subjected to a 2-h coronary occlusion followed by reperfusion; 4 weeks later, rats were injected intramyocardially with either TNNT2-4Fpolycistronic-NIL or LacZ-NIL. Four months post-viral injection, TNNT2-4Fpolycistronic-NIL-treated rats showed a significant reduction in scar size and a significant improvement in left ventricular (LV) systolic cardiac function but not in the LV dilatation associated with chronic IHF. A mitosis reporter system developed in our lab showed significant induction of CM mitotic activity in TNNT2-4Fpolycistronic-NIL-treated rats.
CONCLUSION: This study demonstrates, for the first time, that TNNT2-4Fpolycistronic-NIL gene therapy induces CM cell cycle re-entry in chronic IHF and improves LV function, and that this salubrious effect is sustained for at least 4 months. Given the high prevalence of chronic IHF, these results have significant clinical implications for developing a novel treatment for this deadly disease.
Aim: To describe the duration of desaturation and bradypnea in postoperative opioid-naïve and chronic opioid patients within the first four hours following opioid administration in addition to the chronic dose, using a continuously wireless monitoring system.

Patients: 691 patients included from two previous WARD (Wireless Assessment of Respiratory and circulatory Distress) projects. Continuous wireless monitoring data of peripheral tissue oxygenation (SpO2) and respiratory rate (RR) was conducted in postoperative patients. Data were stratified into opioid-naïve and chronic opioid patients, based on their preoperative opioid history. Patients who did not receive opioids postoperatively were served as the control group. Data was evaluated one hour before and four hours after opioid administration. The primary outcome was the cumulative duration of SpO2 \<88%.
Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
PROBLEM TO BE SOLVED: To obtain a new compound isolated and purified from a cultured product with a specific actinomyces belonging to the genus Streptomyces, having excellent activity in calcium inflow depression, having possibility to become a calcium inflow inhibitor and useful for an anti-platelet agent, an antihypertensive agent or the like. SOLUTION: This new compound is expressed by formula I (wherein R1 is H, OCOCHCHCOOH or the like), e.g. a TS155-2 compound of formula II. The compound of formula I is obtained by culturing a microorganism having ability of producing the compound [e.g. TS-7155 strain deposited in the National Institute of Bioscience and Human-technology, Agency of Industrial Science and Technology, MITI as the Accession number of FERM P-17,212] to produce the compound itself and by collecting the compound. The culture of the microorganism is carried out in a culture medium containing a carbon source (e.g. Soluble starch), a nitrogen source (e.g. defatted soybean powder) and an inorganic salt (e.g. CaCO3) preferably by shaking culture. The collection of the compound is carried out by separating microorganism cells through filtration, etc., and by extracting and purifying the filtrate or the like.
Intraoperative bleeding during large loop excision of the transformation zone (LLETZ)-conization can be achieved by two modes of electrocoagulation, spray coagulation and forced coagulation. Spray coagulation is a superficial coagulation mode, whereas forced coagulation is a deep tissue coagulation mode. It is unknown, whether spray or forced coagulation is superior regarding intraoperative hemostasis and other outcome Parameters such as postoperative bleeding and postoperative pain. Therefore, the investigator designed a randomized clinical trial of 120 women undergoing large loop excision of the transformation zone (LLETZ)-conization for cervical dysplasia, comparing the two coagulation modes, spray coagulation and forced coagulation, The primary outcome of the study is time to complete hemostasis measured in seconds, secondary outcomes are intraoperative blood loss measured as difference in serum hemoglobin pre- and postoperatively, postoperative pain according to a 10 step VAS scale, and postoperative bleeding complications, defined as necessity to intervene surgically for vaginal bleeding up to 14 days postoperatively. The study Population consists of women undergoing LLETZ-conization for histologically proven cervical dysplasia. The study hypothesis states that the difference in the mean time until complete hemostais will be at least 1/3 shorter in women randomized to spray coagulation. With a study Population of 120 women, this study has a power of \>80% to detect a difference of 1/3 of the mean coagulation time until complete hemostais based on an anticipated mean time of 85 seconds.
FIELD: chemistry. ^ SUBSTANCE: invention relates to compounds of formula (I) given below or pharmaceutically acceptable salts thereof: ^ [where: each of X, Y, Z and W independently denotes a methane group which optionally contains substitutes selected from a group of substitutes , or a nitrogen atom (except when all elements X, Y, Z and W denote a methane group which optionally contain substitutes selected from the group of substitutes ); A denotes -(C(R3)(R4))m1-; B denotes -O-; D denotes -C(O)-; m1 equals 0; Q denotes a methane group or a nitrogen atom; R denotes a group of formula (II) ^ , where R6 denotes a lower alkyl group; R7 and R8, together with the nitrogen atom with which they are bonded, form a 5-6-member nitrogen-containing aliphatic heterocyclic group; and where the group of substitutes includes the following substitutes. Group of substitutes : halogen atom, hydroxyl group, lower alkyl group, alkoxyl group (said group can be substituted with a cycloalkyl group), amino group, mono- or disubstituted lower alkylamino group, aryl group (said group can be substituted with a halogen atom, a -SO2CH3 group), aryloxy group (said group can be substituted with a halogen atom), heteroaryl group, where 'heteroaryl group' denotes a 5- or 6-member monocyclic saturated or unsaturated group containing 1-2 heteroatoms selected from an oxygen atom or a nitrogen atom (said group can be substituted with an alkoxyl group, alkyl group). The invention also relates to a histamine 3 receptor antagonist, histamine 3 receptor inverse agonist, a prophylactic or medicinal agent, as well as a pharmaceutical composition. ^ EFFECT: obtaining novel biologically active compounds having histamine H3 receptor antagonist or inverse agonist action. ^ 15 cl, 57 ex, 1 tbl
The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
Sedation-analgesia is provided with dexmedetomidine-esketamine combination for up to 14 days or until discharge from the ICU. The formulation consists of dexmedetomidine 200 μg/2 ml and esketamine 100 mg/4 ml, diluted with normal saline to a total volume of 50 ml, resulting in a dexmedetomidine concentration of 4 μg/ml and an esketamine concentration of 2 mg/ml.
Er,Cr:YSGG laser was applied in a non-contact manner on the pulp tissue from a distance of 3-4 mm for ten seconds, with an energy intensity of 25 mL, output power of 0.5 W, and frequency of 20 Hz. The MZ6 laser tip was used for application.
The invention discloses a corylopsis sinensis root-bark and radix ophiopogonis dracaenoidis-flavor pudding. The corylopsis sinensis root-bark and radix ophiopogonis dracaenoidis-flavor pudding is prepared by taking corylopsis sinensis root-bark and radix ophiopogonis dracaenoidis as raw materials and adding poria with hostwood and valerian root. The pudding fully utilizes the nutritive values of the corylopsis sinensis root-bark and the radix ophiopogonis dracaenoidis, and is combined with the traditional Chinese medicines to achieve a synergistic effect, so that the pudding has the effects of clearing away the heart fire and tranquillizing as well as moistening dryness and dispelling melancholy. The prepared finished product is sweet and delicious, has remarkable health care functions, and can obviously relieve the discomfort of people with palpitation, insomnia and dreaminess after being eaten for a long time. The corylopsis sinensis hemsl. and radix ophiopogonis dracaenoidis-flavor pudding has the advantages of simple preparation technology, convenience in operation and perfect health care functions, thus meeting the demand of market development.